536-25-4

Basic information

• Product Name: Methyl 3-amino-4-hydroxybenzoate
• Synonyms: ORTHOFORM;ORTHOCAINE;3-Amino-4-hydroxybenzoic acid methyl ester;3-amino-4-hydroxy-benzoicacimethylester;Aminobenz;Methyl 4-hydroxy-3-aminobenzoate;Methyl m-amino-p-hydroxybenzoate;Orthoderm
• CAS NO: 536-25-4
• Molecular Formula: C₈H₉NO₃
• Molecular Weight: 167.16
• EINECS: 208-627-3
• Product Categories: Aromatic Esters;Acids & Esters;Anilines, Amides & Amines;Phenols;Esters;Phenyls & Phenyl-Het;Amines;Aromatics;Intermediates;Miscellaneous Reagents
• Mol File: 536-25-4.mol
• Article Data: 42

Chemical Properties

• Melting Point: 141-143
• Boiling Point: 295.73°C (rough estimate)
• Flash Point: 151.444 °C
• Appearance: /Solid
• Density: 1.2917 (rough estimate)
• Vapor Pressure: 0.000111mmHg at 25°C
• Refractive Index: 1.5810 (estimate)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 8.15±0.18(Predicted)
• CAS DataBase Reference: Methyl 3-amino-4-hydroxybenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 3-amino-4-hydroxybenzoate(536-25-4)
• EPA Substance Registry System: Methyl 3-amino-4-hydroxybenzoate(536-25-4)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22
• RTECS: DG2625000
• TSCA: Yes
• HazardClass: IRRITANT
• Hazardous Substances Data: 536-25-4(Hazardous Substances Data)

Usage

Chemical Properties

Beige Solid

Uses

Anesthetic (topical).

InChI:InChI=1/C8H9NO3/c1-12-8(11)5-2-3-7(10)6(9)4-5/h2-4,10H,9H2,1H3

Upstream product

• 99-42-3 methyl (4-hydroxy-3-nitro)benzoate 
• 67-56-1 methanol 
• 616-82-0 3-nitro-4-hydroxybenzoic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 1571-72-8 3-amino-4-hydroxybenzoic acid 
• 75-36-5 acetyl chloride 
• 91-66-7 N,N-diethylaniline 

Downstream Products

• 136663-21-3 methyl 2-methyl-1,3-benzoxazole-5-carboxylate 
• 126360-59-6 methyl 3-(N-acetyl)amino-4-hydroxybenzoate 
• 82525-66-4 3-(2-chloro-acetylamino)-4-hydroxy-benzoic acid methyl ester 
• 82525-67-5 4-hydroxy-3-{[N-(2-hydroxy-5-methoxycarbonyl-phenyl)-glycyl]-amino}-benzoic acid methyl ester 
• 31039-94-8 4-hydroxy-3-phenylazo-benzoic acid methyl ester 
• 175402-07-0 2-(4-Cyano-phenyl)-benzooxazole-5-carboxylic acid methyl ester 
• 207235-69-6 2-benzyloxycarbonylamino-1-hydroxy-1-[5-(methoxycarbonyl)benzoxazol-2-yl]-3-phenylpropane 
• 534571-98-7 methyl 2-cyano-3,4-dihydro-2H-1,4-benzoxazine-6-carboxylate 
• 737802-27-6 N-[5-(1-ethyl-1-hydroxy-propyl)-2-hydroxy-phenyl]-acetamide 
• 648449-54-1 3,4-dihydro-2H-benzo[1,4]oxazine-6-carboxylic acid ester hydrochloride 
• 7450-57-9 3-amino-4-hydroxybenzoic acid hydrazide 
• 179950-77-7 (+/-)-2-methyl-3-oxo-6-(methoxycarbonyl)-3,4-dihydro-2H-1,4-benzoxazine 
• 72730-39-3 methyl 2-thioxo-2,3-dihydrobenzo[d]oxazole-5-carboxylate 
• 1050210-04-2 4-hydroxy-3-octanoylaminobenzoic acid methyl ester 

Relevant articles and documents

Synthesis and biological activities of some Novel 2-Amino-(5 or 7-Substituted- 2-Oxoindolin-3-Ylidene) Benzoxazole-5-Carbohydrazide derivatives

A series of 2-amino-(5 or 7-substituted-2-oxoindolin-3-ylidene) benzoxazole-5-carbohydrazide derivatives were synthesized by treating 2-aminobenzoxazole-5-carbohydrazide with different substituted isatins. All the synthesized derivatives (VI a-l) were screened for their in vitro anticancer (against HeLa, IMR-32 & MCF-7 cancer cell lines), antioxidant (against DPPH radicals) and antimicrobial activities. The results of these studies showed the dose dependant anticancer, antioxidant and antimicrobial activities of the test compounds and the IC50 values of some compounds were comparable with their standard agent. The test compounds having substitution with different electron withdrawing groups at C-5 position showed more potent anticancer, antioxidant and antibacterial activities than those at C-7 position.

Heterocyclic substituted biphenyl compound as well as preparation method and application thereof

The invention discloses a heterocyclic substituted biphenyl compound as well as a preparation method and application thereof. According to the present invention, the compound can block the PD-1/PD-L1 signal pathway, and can be used as the immune checkpoint PD-1/PD-L1 small molecule inhibitor; and according to the compound disclosed by the invention, the metabolic stability is improved while the high binding rate with PD-L1 protein is maintained. A hydrophilic group is introduced to a heterocyclic ring, and the PD-1/PD-L1 inhibitory activity is improved.

Identification of ortho-hydroxy anilide as a novel scaffold for lysine demethylase 5 inhibitors

Fe(II)/α-ketoglutarate-dependent lysine demethylases (KDMs) are attractive drug targets for several diseases including cancer. In this study, we designed and screened ortho-substituted anilides that are expected to function as Fe(II) chelators, and identified ortho-hydroxy anilide as a novel scaffold for KDM5A inhibitors. Treatment of human lung cancer A549 cells with a prodrug form of 4-carboxy-2-hydroxy-formanilide (9c) increased trimethylated lysine 4 on histone H3 level, suggesting KDM5 inhibition in the cells.